Peter L. Greenberg

Active 1971–2025

83
Papers
23,361
Citations
64
h-index
80
i10-index

Citations

Citations per year for Peter L. Greenberg1971: 1 citations1972: 3 citations1973: 5 citations1974: 6 citations1976: 5 citations1977: 4 citations1979: 7 citations1980: 7 citations1981: 1 citations1982: 3 citations1983: 5 citations1984: 5 citations1985: 7 citations1986: 4 citations1987: 9 citations1988: 10 citations1989: 12 citations1990: 9 citations1991: 4 citations1992: 12 citations1993: 5 citations1994: 11 citations1995: 10 citations1996: 7 citations1997: 10 citations1998: 23 citations1999: 20 citations2000: 41 citations2001: 33 citations2002: 55 citations2003: 61 citations2004: 51 citations2005: 74 citations2006: 86 citations2007: 124 citations2008: 123 citations2009: 130 citations2010: 131 citations2011: 101 citations2012: 126 citations2013: 218 citations2014: 153 citations2015: 162 citations2016: 136 citations2017: 135 citations2018: 152 citations2019: 482 citations2020: 476 citations2021: 599 citations2022: 486 citations2023: 430 citations2024: 583 citations2025: 269 citations2026: 7 citations1975: no citations, so this year is not shown1978: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,939 citing papers, 29% of this breakdownGermany: 543 citing papers, 8.1% of this breakdownItaly: 479 citing papers, 7.2% of this breakdownUnited Kingdom: 436 citing papers, 6.5% of this breakdownFrance: 378 citing papers, 5.6% of this breakdownChina: 290 citing papers, 4.3% of this breakdownSpain: 255 citing papers, 3.8% of this breakdownNetherlands: 219 citing papers, 3.3% of this breakdownCanada: 202 citing papers, 3% of this breakdownJapan: 191 citing papers, 2.9% of this breakdownSweden: 169 citing papers, 2.5% of this breakdownAustralia: 157 citing papers, 2.3% of this breakdown
0%29%Other 21.5%

Fields

  • Medicine72.8%
  • Biochemistry, Genetics and Molecular Biology19.8%
  • Immunology and Microbiology3%
  • Computer Science1%
  • Chemistry0.5%
  • Environmental Science0.4%
  • Other2.5%

Topics

  • Acute Myeloid Leukemia Research19%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment6.1%
  • Hematopoietic Stem Cell Transplantation4.3%
  • Acute Lymphoblastic Leukemia research2.9%
  • Histone Deacetylase Inhibitors Research2.2%
  • Chronic Myeloid Leukemia Treatments2.1%
  • Other63.4%

Coauthors

All papers

Open in search
  1. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Akifumi Takaori‐Kondo, Takayuki Ishikawa, Shigeru Chiba, Senji Kasahara, Yasushi Miyazaki, Agnès Viale, Kety Huberman, Pierre Fenaux, Monika Beličková, Michael R. Savona, Virginia M. Klimek, Fábio Pires de Souza Santos, Jacqueline Boultwood, Ιoannis Kotsianidis, Valeria Santini, Françesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Kazuma Ohyashiki, Carlo Finelli, Maria Teresa Voso, Lee‐Yung Shih, Michaëla Fontenay, Joop H. Jansen, José Cervera, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Luca Malcovati, Mario Cazzola, Seishi Ogawa, Eva Hellström‐Lindberg, Elli Papaemmanuil - NEJM Evidence 2022 cited by 813

  2. Revised International Prognostic Scoring System for Myelodysplastic Syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Teresa Vallespı́, Arjan A. van de Loosdrecht, Ulrich Germing, Detlef Haase - Blood 2012 cited by 3,140

  3. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jacqueline Boultwood, Fábio Pires de Souza Santos, Julie Schanz, Senji Kasahara, Takayuki Ishikawa, Hisashi Tsurumi, Akifumi Takaori‐Kondo, Toru Kiguchi, Chantana Polprasert, John M. Bennett, Virginia M. Klimek, Michael R. Savona, Monika Beličková, Christina Ganster, Laura Palomo, Guillermo Sanz, Lionel Adès, Matteo Giovanni Della Porta, Harold K. Elias, Alexandra Smith, Yesenia Werner, Minal Patel, Agnès Viale, Katelynd Vanness, Donna Neuberg, Kristen E. Stevenson, Kamal Menghrajani, Kelly L. Bolton, Pierre Fenaux, Andrea Pellagatti, Uwe Platzbecker, Michael Heuser, Peter Valent, Shigeru Chiba, Yasushi Miyazaki, Carlo Finelli, Maria Teresa Voso, Lee‐Yung Shih, Michaëla Fontenay, Joop H. Jansen, José Cervera, Yoshiko Atsuta, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Peter L. Greenberg, Mario Cazzola, Eva Hellström-Lindberg, Seishi Ogawa, Elli Papaemmanuil - Nature Medicine 2020 cited by 636

  4. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Amer M. Zeidan, Lionel Adès, Amit Verma, Michael R. Savona, Abderrahmane Laadem, Aziz Benzohra, Jennie Zhang, Anita Rampersad, Diana Dunshee, Peter G. Linde, Matthew L. Sherman, Rami S. Komrokji, Alan F. List - New England Journal of Medicine 2020 cited by 537

  5. Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marı́a A. Blasco, Peter L. Greenberg, Phyllis J. Snyder, Teri E. Klein, Russ B. Altman, Atul J. Butte, Euan A. Ashley, Mark Gerstein, Kari C. Nadeau, Hua Tang, M Snyder - Cell 2012 cited by 1,320

  6. International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

    Authors: , , , , , , , , , , , , , , - Blood 1997 cited by 4,457

  7. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Detlef Haase, Heinz Tüchler, Peter L. Greenberg, Seishi Ogawa, Eva Hellström‐Lindberg, Mario Cazzola - Blood 2020 cited by 293

  8. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Benoit Destenaves, Xiaobin Yuan, Kun Yu, Sara Dar, Lernik Ohanjanian, Keisuke Kuida, Jianjun Xiao, Catherine Scholz, Antonio Gualberto, Uwe Platzbecker - Leukemia 2021 cited by 178

  9. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michaëla Fontenay, Olivier Kosmider, Michal Bar‐Natan, David P. Steensma, Richard M. Stone, Michael Heuser, Felicitas Thol, Mario Cazzola, Luca Malcovati, Aly Karsan, Christina Ganster, Eva Hellström‐Lindberg, Jacqueline Boultwood, Andrea Pellagatti, Valeria Santini, Lynn Quek, Paresh Vyas, Heinz Tüchler, Peter L. Greenberg, Rafael Bejar - Leukemia 2019 cited by 259

  10. Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

    Authors: , , , , , , , , , , , , , , , - New England Journal of Medicine 2006 cited by 1,317

  11. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matteo Della Porta, Kety Huberman, Pierre Fenaux, Monika Beličková, Michael R. Savona, Virginia M. Klimek, Fábio Pires de Souza Santos, Jacqueline Boultwood, Ιoannis Kotsianidis, Valeria Santini, Françesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee‐Yung Shih, Seishi Ogawa, Michaëla Fontenay, Joop H. Jansen, José Cervera, Benjamin L. Ebert, Rafael Bejar, Peter L. Greenberg, Norbert Gattermann, Luca Malcovati, Mario Cazzola, David B. Beck, Eva Hellström‐Lindberg, Elli Papaemmanuil - Blood 2024 cited by 49

  12. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS

    Authors: , , , , , , , , , , , , , , , , , , , , - Blood 2012 cited by 203

  13. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Asya Varshavsky‐Yanovsky, Peter Westervelt, Elizabeth Hollinger, Dorothy A. Shead, Cindy Hochstetler - Journal of the National Comprehensive Cancer Network 2022 cited by 125

  14. Shared and distinct mechanisms of UBA1 inactivation across different diseases

    Authors: , , , , , , , , , , , , , , , , , , - The EMBO Journal 2024 cited by 40

  15. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes

    Authors: , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2013 cited by 282

  16. Molecular taxonomy of myelodysplastic syndromes and its clinical implications

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matteo Giovanni Della Porta, Pierre Fenaux, Monika Beličková, Michael R. Savona, Virginia M. Klimek, Fábio Pires de Souza Santos, Jacqueline Boultwood, Ιoannis Kotsianidis, Valeria Santini, Françesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee‐Yung Shih, Michaëla Fontenay, Joop H. Jansen, José Cervera, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Luca Malcovati, Seishi Ogawa, M. Cazzola, Eva Hellström‐Lindberg, Elli Papaemmanuil - Blood 2024 cited by 73

  17. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1–Risk Myelodysplastic Syndromes

    Authors: , , , , , , , , , , , - Annals of Internal Medicine 2020 cited by 112

  18. Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2013 cited by 284

  19. Time-dependent changes in mortality and transformation risk in MDS

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Arjan A. van de Loosdrecht, Ulrich Germing, Detlef Haase, Peter L. Greenberg - Blood 2016 cited by 175

  20. Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joanne Schindler, Sherri Smith, Huilan Yao, Xiaobin Yuan, Kun Yu, Uwe Platzbecker - Blood 2019 cited by 89

  21. Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2014 cited by 246

  22. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Oncotarget 2017 cited by 189

  23. Azacitidine with or without Entinostat for the treatment of therapy‐related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study

    Authors: , , , , , , , , , , , , , , , , , - British Journal of Haematology 2015 cited by 106

  24. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

    Authors: , , , , , , , , , , , , , , , , , , - Leukemia Research 2007 cited by 509